Biomira Announces Final Survival Results of Phase 2b Trial of Stimuvax®, a Vaccine Developed Under Licence to Cancer Research Technology’s MUC1 Patents
Edmonton, Alberta, Canada, April 28, 2006 — Biomira Inc. today announced final survival results from an exploratory analysis of the Phase 2b clinical trial data. The randomized, open-label trial tested the clinical potential of Stimuvax® in patients with Stage IIIB and IV non-small cell lung cancer (NSCLC). The analysis confirms a median survival in Stage IIIB patients on vaccine being 30.6 months, while Stage IIIB patients on the control had a median survival of 13.3 months.
“Our enthusiasm around Stimuvax® continues,” said Alex McPherson, MD, PhD, President and CEO of Biomira. “These data from the Phase 2b trial are encouraging and have been reviewed by an independent statistician, who confirms our findings. We are in the process of completing the transition of this exciting project to Merck KGaA of Darmstadt, Germany and we have begun manufacturing the vaccine required for the phase 3 study slated to start this summer………”
Cancer Research Technology (CRT) previously granted an exclusive worldwide license to rights to the MUC1 protein antigen for in vivo, ex vivo and in vitro uses in the treatment and diagnosis of cancer. The MUC1 antigen is found on human breast, ovarian, colon and pancreatic cancer cells. Biomira and CRT also entered into a second license agreement, which, among other things, granted Biomira an exclusive worldwide license of CRT’s MUC1 peptide patent rights for treatment and diagnosis of diseases other than cancer.
To view the original press release from Biomira please click here
|
